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The yeast KEX2 protease is the only enzyme that has a proven role in the activation of polypeptide hormones through 
cleavage atpairs of basic residues. The enzyme that fulfils this role in higher eukaryotes has yet to be unequivocally identi- 
fied. In this investigation, a KEX2-1ike calcium-dependent pro ease has been identified in rat hepatic microsomes. The 
enzyme ismembrane-bound, has a pH optimum of 5-6 and converts proalbumin to albumin. More importantly, like 
the KEX2 protease, it meets two other exacting criteria defined by specific mutations in humans. Namely, it does not 
process proalbumin Christchurch (-1 Arg---,Gln) which lacks one of the requisite basic residues and, whilst not itself a 
serine protease, it is inhibited by the reactive center variant, al-antitrypsin Pittsburgh (358 Met~Arg) but not by normal 
~l-antitrypsin. 
Proalbumin convertase; cq-Antritrypsin Pittsburgh; Proalbumin Christchurch; (Liver microsome) 
1. INTRODUCTION 
Proteolytic processing at pairs of basic residues 
is a critical event in the activation of peptide hor- 
mones, neuropeptides and some plasma proteins 
[1,2]. Because of the central importance of the 
cleavage products in man, much attention has 
focused on the identity of the cleaving enzyme. 
Not surprisingly, therefore, a number of different 
proteases have been implicated. The difficulty is to 
decide which of these enzymes is of physiological 
importance. This question has been resolved in the 
case of the yeast (Saccharomyces cerevisiae) where 
mutations in the KEX2 gene, which encodes a pro- 
posed calcium-dependent Golgi enzyme, prevent 
processing at Lys-Arg sequences in the secreted a,- 
factor and killer toxin precursor peptides [3]. Rein- 
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troduction of the gene into deficient strains 
restores the missing proteolytic activity and, hence, 
the killer expression phenotype [4]. This unique 
protease may be a prototype of the mammalian en- 
zyme as it correctly processes a number of purified 
human proproteins and transfection of mam- 
malian cells with the mouse proopiomelanocortin 
gene together with the KEX2 gene results in the 
production of the expected hormones through 
cleavage at the double basic sequences [5]. 
While persuasive, these experiments do not in 
themselves prove that a KEX2-1ike protease is in- 
volved in the in vivo cleavage of mammalian pro- 
proteins. Just as Kex2 mutants facilitated the 
identification of the converting enzyme in yeasts, 
mutations in humans that block proalbumin pro- 
cessing closely define the proalbumin-converting 
enzyme. The peptide Arg-Gly-Val-Phe-Arg-Arg is
cleaved from proalbumin just before secretion 
from the hepatocyte [6]. 
The existence of the circulating variants, pro- 
albumin Christchurch ( -1  Arg~Gln)  [7], pro- 
albumin Lille ( - 2 Arg -~ His) [8], and proalbumin 
Takefu ( -  1 Arg ~ Pro) [9] establish a critical re- 
quirement for a pair of  basic residues at the 
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cleavage site. Proalbumin with this requisite 
dibasic sequence has also been observed in circula- 
tion. This was in a child with a fatal bleeding 
disorder caused by the presence of a variant form 
of arant i trypsin,  a, rantitrypsin Pittsburgh (358 
Met-oArg)  [10]. Here the reactive center, or 
'bait ' ,  of the inhibitor had mutated to Arg, thereby 
directing it against arginyl-specific proteases, 
demonstrably targeting it against hrombin and, by 
implication, against the proalbumin-cleaving en- 
zyme [11]. This was a reasonable deduction based 
on the case history and the fact that ~l-antitrypsin 
and proalbumin are exported from the same 
secretory vesicles in the hepatocyte [12]. 
Based on these criteria, the yeast KEX2 enzyme 
is indeed an appropriate model for a human con- 
vertase; it processes normal human proalbumin 
but not proalbumin Christchurch, and it is in- 
hibited by a~-antitrypsin Pittsburgh but not by 
normal ax-antitrypsin [13]. We report here the 
identification of a KEX2-1ike protease, with these 
same critical properties, present in rat hepatic 
microsome preparations. 
2. MATERIALS AND METHODS 
Human proalbumin and o~rantitrypsin Pittsburgh were 
isolated from the plasma of the affected child [10,11]. Pro- 
albumin Christchurch wasisolated from the plasma ofa hetero- 
zygous carrier [14] and normal rantitrypsin was isolated ft, om 
the plasma of an individual with the MM phenotype as de- 
scribed in [15]. 
Golgi vesicle fractions were prepared as described by Quinn 
and Judah [16]; a critical difference, however, was that no 
EDTA was incorporated in the various sucrose density solu- 
tions. Briefly, livers were homogenized in ice-cold 0.25 M 
sucrose; nuclei, mitoehondria and cell debris wer  removed by 
centrifugation (9500 x gay, 15 min). The supernatant co aining 
the microsomes was layered over 1.3 M sucrose and centrifuged 
(SW28 rotor, 85 000 x gay, 90 min). Membranes from the inter- 
face were diluted with 2 M sucrose and successively overlayered 
with 1.1, 0.85 and 0.25 M sucrose and centrifuged (TI60 rotor, 
200000 Xg~, 120 min). Membranes from the 0.85/0.25 M and 
1.1/0.85 M sucrose interfaces wererecovered, suspended in 
0.25 M sucrose and pelleted (TI60 rotor, 200000 x ga~, 30 rain). 
Recovered fractions, designated light and heavy membranes 
respectively, were resuspended in approx. 2 vols of 0.1 M 
sucrose. Both fractions appeared similar on electron mi- 
croscopy [17] and contained similar amounts f proalbumin- 
converting activity. 
Washed, pelleted microsomal fractions were lysed in 1.5°70 
Triton X-100 and ghosts removed by centrifugation prior t  
assay. Assay conditions are detailed in the figure l gends. 
Protein electrophoresis was carried out in 1070 agarose gels us-
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ing 0.1 M Tris/barbitone buffer, pH 8.6, and 63Ni and ~25I 
autoradiography was carried out as in [11]. 
3. RESULTS AND DISCUSSION 
The conversion of the proalbumin to albumin 
was assessed by an increase in electrophoretic 
mobility and concomitant ability to bind 63Ni, 
which results from conversion to the mature 
albumin N-terminal sequences of Asp-Ala-His 
[14]. Both light and heavy membrane fractions 
converted normal human proalbumin to albumin 
(fig.l, lanes 3,10). Proalbumin Christchurch ( -1  
Arg ~ Gln), which is readily cleaved by trypsin-like 
enzymes, however, was unaffected by the vesicle 
protease (lane 7). The presence of normal 
al-antitrypsin (lane 4), or a,2-macroglobulin (lane 
8) had no effect on proalbumin conversion, 
however, conversion was selectively inhibited by 
the reactive center variant t~l-antitrypsin Pitts- 
burgh (358 Met-~ Arg) (lane 5). Like the KEX2 
protease, conversion was also inhibited by EDTA 
(lane 9). 
The hepatic enzyme has other features in com- 
mon with its yeast counterpart (fig.2A) [18]. It is 
membrane-bound and its converting activity 
pelleted with the membranes on simple freeze- 
thawing but was released on treatment with 1.5°70 
Triton X-100 (fig.2A, lane 2); the washed ghosts 
lacked activity (lane I). The serine protease in- 
hibitor PMSF (lane 3) had no effect on conversion, 
neither did the aspartyl protease inhibitor 
pepstatin (lane 8), nor the thiol protease inhibitor 
iodoacetamide (lane 7). Neither TLCK (lane 4) nor 
~-mercaptoethanol (lane 11) gave any inhibition. 
However, both PCMB (lane 5) and Hg 2+ were po- 
tent inhibitors, suggesting the presence of a critical 
thiol group not directly involved in catalysis. The 
inhibition by EDTA (lane 10) was reversed by the 
addition of Ca 2+ but not by Mg 2+ (not shown). 
Zn z+ caused partial inhibition (lane 6), the extent 
of which was dependent on the Ca 2+ concentration 
(not shown). The most striking difference between 
the yeast and hepatic enzymes is their pH op- 
t imum, pH 7.2 in the case of yeast [18] and pH 5-6 
for the hepatic enzyme (fig.2B). The pH required 
for optimal proalbumin conversion, however, cor- 
responds well to the pH of 5.5 found in secretory 
vesicles [19]. 
These results show that this hepatic protease 
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Fig. 1. Agarose gel electrophoresis (pH 8.6) showing the specific conversion of human proalbumin to albumin. 63Ni autoradiograph, 
confirming correct cleavage at the Arg-Arg site is offset above the Coomassie blue-stained protein electrophoresis pattern. Lanes: 1,6, 
proalbumin Christchurch; 2, proaibumin; 3,10, proalbumin + membrane ¢~tract; 4, proalbumin + otl-antitrypsin M and membrane 
extract; 5, proalbumin + oLrantitrypsin Pittsburgh and membrane extract; 7, proalbumin Christchurch + membrane extract; 8, pro- 
albumin + oa-macroglobulin a d membrane extract; 9, proalbumin + EDTA and membrane extract; 11, markers of albumin plus 
proalbumin Christchurch. Incubations were performed for 3.5 h at 37°C in 10/~1 of 50 mM Hepes-Tris (pH 6.0) containing 20 mM 
Ca 2+, 1.5o/0 Triton X-100, l0 mM PMSF and 1 mM iodoacetamide. Where added, proalbumin and proalbumin Christchurch were 
present at 25/zg, otrantitrypsin, otrantitrypsin Pittsburgh and a2-macroglobulin at 2.5/~g, and EDTA at 40 raM. Where added, 25/~g 
(protein) of microsomal membranes were used. Washed and pelleted membrane fractions were solubilized in 50 mM Hepes-Tris (pH 
6.0) containing 20 mM CaC12 and 1.5°70 Triton X-100 and the membrane ghosts removed before incubation. Serum protein elec- 
trophoresis was performed on 5/A of the assay solutions after addition of 63Ni. 
Fig.2. (A) Autoradiograph of agarose gel electrophoresis plate, showing conversion of ~25I-labeled human proalbumin to albumin by 
Triton X-100-solubilized Golgi membrane xtracts (lanes 2-11) and washed ghosts (lane 1). Lanes: 1,2, no additions; additions: 3, 
20 mM PMSF; 4, 1 mM TLCK; 5, 1 mM PCMB; 6, 5 mM ZnC12; 7, 2 mM iodoacetamide; 8, 1 mM pepstatin; 9, 1 mM leupeptin; 
10, 30 mM EDTA; 11, 3 mM B-mercaptoethanol. Each assay contained 25/zg (protein) membrane extract in 10/~1 of 50 mM Hepes- 
Tris (pH 6.0) containing 20 mM CaCI2 and 1.5070 Triton X-100 incubation was for 3 h at 37°C. (B) Effect of pH on proaibumin conver- 
sion. Conditions as for panel A except hat the buffer was (lanes): 1, 0.1 M acetate, pH 3.7; 2, 0.1 M acetate, pH 4.5; 3, 0.1 M acetate, 
pH 5.5; 4, 0.1 M Hepes-Tris, pH 5.3; 5, 0.1 M Hepes-Tris, pH 6.0; 6, 0.1 M Hepes-Tris, pH 7.0; 7, 0.1 M Hepes-Tris, pH 8.0. 
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meets all the requirements of a proalbumin conver- 
tase. It is located in the Golgi and secretory 
vesicles, is membrane-bound, and is fully active at 
the pH of secretory vesicles. It correctly cleaves 
proalbumin at the Arg-Arg sequence but does not 
cleave the Arg-Gln sequence in proalbumin Christ- 
church which is very susceptible to tryptic leavage 
[13]. Its most important claim to authenticity, 
however, is that while being unaffected by the 
classical serine protease inhibitors, including nor- 
mal Cel-antitrypsin, it is specifically inhibited by the 
mutant inhibitor C~l-antitrypsin Pittsburgh. This 
confirms the prediction, from the clinical aspects 
of the Pittsburgh case, namely that the mutant 
antitrypsin was acting as an intracellular inhibitor 
of proalbumin conversion and that the unique 
observation of normal circulating proalbumin was 
consequential to the unique inhibitory site muta- 
tion in a~l-antitrypsin Pittsburgh [10,11]. 
The hepatic enzyme has another claim to 
authenticity in that it is similar to the KEX2 pro- 
tease, which fulfils an analogous role in yeast. It is 
possible that similar proteases are involved in the 
processing of other mammalian proproteins. Very 
recently, Davidson et al. [20] identified a similar 
enzyme in insulin-secretory granules. This 
Ca2÷-dependent protease, which correctly pro- 
cesses proinsulin, is quite distinct from any 
previously proposed proinsulin convertase, but is 
remarkably similar to the proalbumin convertase 
described here in terms of its subcellular location, 
inhibitory properties and pH optimum (pH 
5.0-6.0). Preliminary evidence (from our 
laboratory) indicates that microsomes from rat 
atria, the site of atrial natriuretic hormone produc- 
tion, contain a similar protease which is both 
Ca2+-dependent and inhibitible by a,l-antitrypsin 
Pittsburgh. Cleavage of proatrial natriuretic hor- 
mone occurs at a Pro-Arg sequence [21], sug- 
gesting that the convertase for mono- or dibasic 
sites could be related. It is possible that a family of 
CaZ+-dependent proteases may be involved in the 
processing of other mammalian proproteins. 
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